Merck wins FDA nod for Keytruda as adjuvant kidney cancer treatmentMerck & Co has chalked up another win in drive to move PD-1 inhibitor Keytruda earlier in the Share XMerck wins FDA nod for Keytruda as adjuvant kidney cancer treatmenthttps://pharmaphorum.com/news/merck-wins-fda-nod-for-keytruda-as-adjuvant-kidney-cancer-treatment/
Gilead tags Merck for first-line triple negative breast cancer trialTake two recently-approved immunotherapies for triple negative breast cancer (TNBC), put them together, and what do you get? Share XGilead tags Merck for first-line triple negative breast cancer trialhttps://pharmaphorum.com/news/gilead-tags-merck-for-first-line-triple-negative-breast-cancer-trial/
AZ/Daiichi partner with Merck on first-line lung cancer trialThe dominance of Merck & Co’s Keytruda in the treatment of previously-untreated non-small cell lung cancer (NSCLC) means Share XAZ/Daiichi partner with Merck on first-line lung cancer trialhttps://pharmaphorum.com/news/az-daiichi-partner-with-merck-on-first-line-lung-cancer-trial/
Merck gets EU approval for Keytruda in triple-negative breast cancerMerck & Co has claimed EU approval for Keytruda in triple-negative breast cancer (TNBC), a particularly hard-to-treat form Share XMerck gets EU approval for Keytruda in triple-negative breast cancerhttps://pharmaphorum.com/news/merck-gets-eu-approval-for-keytruda-in-triple-negative-breast-cancer/
BMS strikes back against Merck in EU oesophageal cancer marketMerck & Co’s Keytruda become the first cancer immunotherapy to be approved as a first-line oesophageal cancer treatment Share XBMS strikes back against Merck in EU oesophageal cancer markethttps://pharmaphorum.com/news/bms-strikes-back-against-merck-in-eu-oesophageal-cancer-market/
Roche scores adjuvant lung cancer approval for TecentriqRoche has claimed an earlier-than-expected FDA approval for its checkpoint inhibitor Tecentriq in non-small cell lung cancer (NSCLC), Share XRoche scores adjuvant lung cancer approval for Tecentriqhttps://pharmaphorum.com/news/roche-scores-early-adjuvant-lung-cancer-approval-for-tecentriq/
Keytruda’s liver cancer approval secured by new studyMerck & Co’s FDA approval for Keytruda in advanced liver cancer looks secure, after an Asian clinical trial Share XKeytruda’s liver cancer approval secured by new studyhttps://pharmaphorum.com/news/keytrudas-liver-cancer-approval-secured-by-new-study/
ESMO21: Libtayo extends survival in first-line NSCLC, challenging KeytrudaThere’s no shortage of cancer immunotherapies trying to knock Merck & Co’s Keytruda off the top of the Share XESMO21: Libtayo extends survival in first-line NSCLC, challenging Keytrudahttps://pharmaphorum.com/news/esmo21-libtayo-extends-survival-in-first-line-nsclc-challenging-keytruda/
Keytruda backed by NICE for late-stage oesophageal cancerMSD’s Keytruda has become the first immunotherapy cleared by NICE for previously-untreated patients with advanced oesophageal cancer, making Share XKeytruda backed by NICE for late-stage oesophageal cancerhttps://pharmaphorum.com/news/keytruda-backed-by-nice-for-late-stage-oesophageal-cancer/
